Abstract
Glycated hemoglobin is widely used in the management of diabetes mellitus. At least 300,000 Americans with diabetes mellitus have the hemoglobin (Hb) C or S trait. The accuracy of HbA 1c methods can be adversely affected by the presence of these traits. We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA 1c. Results for each sample type were compared with those from the CLC 330 comparative method (Primus Diagnostics, Kansas City, MO). After correcting for calibration bias by comparing results from the homozygous HbA group, method bias attributable to the presence of HbC or HbS trait was evaluated with a clinically significant difference being more than 10% (ie, 0.6% at 6% HbA 1c). One immunoassay method exhibited clinically significant differences owing to the presence of HbC and HbS traits. ©American Society for Clinical Pathology.
Original language | English (US) |
---|---|
Pages (from-to) | 136-140 |
Number of pages | 5 |
Journal | American Journal of Clinical Pathology |
Volume | 130 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1 2008 |
Externally published | Yes |
Bibliographical note
Generated from Scopus record by KAUST IRTS on 2023-09-20ASJC Scopus subject areas
- Pathology and Forensic Medicine